Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $9.65 in the prior trading day, Vir Biotechnology Inc (NASDAQ: VIR) closed at $9.69, up 0.36%. In other words, the price has increased by $0.36 from its previous closing price. On the day, 0.93 million shares were traded.
Ratios:
Our goal is to gain a better understanding of VIR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.94 and its Current Ratio is at 8.94. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on January 29, 2024, Downgraded its rating to Neutral and sets its target price to $9 from $23 previously.
On September 08, 2023, BofA Securities Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $23 to $14.
JP Morgan Upgraded its Neutral to Overweight on March 06, 2023, whereas the target price for the stock was revised from $35 to $34.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 18 ’25 when George Scangos bought 10,964 shares for $9.81 per share.
Sabatini Brent sold 1,562 shares of VIR for $14,291 on Feb 13 ’25. The SVP, Chief Accounting Officer now owns 28,189 shares after completing the transaction at $9.15 per share. On Feb 13 ’25, another insider, Brent Sabatini, who serves as the Officer of the company, bought 1,562 shares for $9.15 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 16.97 while its Price-to-Book (P/B) ratio in mrq is 1.07.
Stock Price History:
Over the past 52 weeks, VIR has reached a high of $14.45, while it has fallen to a 52-week low of $6.56. The 50-Day Moving Average of the stock is 6.81%, while the 200-Day Moving Average is calculated to be 8.80%.
Shares Statistics:
A total of 136.71M shares are outstanding, with a floating share count of 88.05M. Insiders hold about 36.07% of the company’s shares, while institutions hold 51.16% stake in the company.
Earnings Estimates
The current assessment of Vir Biotechnology Inc (VIR) involves the perspectives of 7.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.88, with high estimates of -$0.68 and low estimates of -$1.09.
Analysts are recommending an EPS of between -$3.7 and -$4.02 for the fiscal current year, implying an average EPS of -$3.92. EPS for the following year is -$3.74, with 8.0 analysts recommending between -$2.6 and -$5.28.
Revenue Estimates
A total of 8 analysts have provided revenue estimates for VIR’s current fiscal year. The highest revenue estimate was $101.6M, while the lowest revenue estimate was $61.8M, resulting in an average revenue estimate of $68.65M. In the same quarter a year ago, actual revenue was $86.18M
